logo-loader
viewAstraZeneca

Still some downside at AstraZeneca says Zak Mir

Trump may have adopted rival's drug plans

AstraZeneca PLC (LON:AZN) shares have fallen recently with the sector on the back of fears US drugs may be made cheaper by new chairman Donald Trump.

The new president has seemingly stolen a policy from his presidential rival Hillary Clinton, says Zak Mir, Tip TV’s technical analyst.

Astra has very important cancer drug trials underway with results due next year.

The price chart shows falls in October and November and with the main support level at £38 there may be a couple of pounds more on the downside before bargain hunters appear says Mir.

Quick facts: AstraZeneca

Price: 7690 GBX

LSE:AZN
Market: LSE
Market Cap: £100.91 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO highlights 'very strong assay and platform development progress'

VolitionRx Limited's (NYSEAMERICAN:VNRX) president and CEO Cameron Reynolds recaps on what he describes as a year of 'very strong progress' in assay and platform development with its Nu.Q Capture program and epigenetic toolkit Nu.Q Vet. Heading into 2020, Reynolds says the company's well...

2 days, 17 hours ago

2 min read